[go: up one dir, main page]

WO2005094812A1 - Préparation contenant du natéglinide - Google Patents

Préparation contenant du natéglinide Download PDF

Info

Publication number
WO2005094812A1
WO2005094812A1 PCT/JP2005/006459 JP2005006459W WO2005094812A1 WO 2005094812 A1 WO2005094812 A1 WO 2005094812A1 JP 2005006459 W JP2005006459 W JP 2005006459W WO 2005094812 A1 WO2005094812 A1 WO 2005094812A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
pharmaceutical composition
composition according
weight
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2005/006459
Other languages
English (en)
Japanese (ja)
Inventor
Kunikazu Suzuki
Wataru Wakui
Akira Yabuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Priority to JP2006511837A priority Critical patent/JP5168712B2/ja
Publication of WO2005094812A1 publication Critical patent/WO2005094812A1/fr
Priority to KR1020067020510A priority patent/KR101175120B1/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention relates to a formulation of nateglinide useful as a diabetes drug, and more particularly to an orally disintegrating tablet of nateglinide.
  • Nateglinide [N-Dragon Compound: N- (trans-4-isopropylcyclohexylcarbol) -D-phenalanine] has an excellent hypoglycemic effect by oral administration and is known to be useful as a therapeutic drug for diabetes. (Patent Document 1).
  • nateglinide drug substance has a very strong bitter taste
  • ease of ingestion is required.
  • Nateglinide is an excellent drug for improving postprandial hyperglycemia, and thus required administration before meals.
  • conventional preparations require water to be taken at the same time as the drug at the time of administration, and there has been a demand for a preparation that does not require water at the time of ingestion.
  • nateglinide drug substance has an extremely strong bitter taste as described above, when an orally disintegrating tablet is produced by a usual method, it has a bitter taste in the oral cavity at the time of ingestion, which causes discomfort to the user and is not practical.
  • Patent Documents 2 to 6 there has been known an invention relating to a preparation containing nateglinide, but there is no known invention relating to an orally disintegrating tablet having reduced bitterness.
  • Patent Document 1 Japanese Patent Publication No. 4 15221
  • Patent Document 2 WO98Z22105
  • Patent Document 3 WOO 1/21159
  • Patent Document 4 WO0lZ47557
  • Patent Document 5 WO02Z34254
  • Patent Document 6 WO02Z40010 Disclosure of the invention
  • An object of the present invention is to provide a pharmaceutical preparation containing nateglinide as an active ingredient, which does not cause bitterness and / or a preparation.
  • bitterness was reduced even when disintegrated in the oral cavity by containing nateglinide and at least one of organic or organic acids, sweeteners, and flavors. It has been found that a preparation can be provided, and the present invention has been completed.
  • the present invention provides a pharmaceutical composition containing nateglinide as an active ingredient, further comprising at least one selected from the group consisting of an organic acid or an inorganic acid, a sweetener and a flavoring agent. Things.
  • the organic acid is selected from the group consisting of ascorbic acid, citric acid, anhydrous citric acid, succinic acid, tartaric acid, fumaric acid, and malic acid
  • the inorganic acid is sodium hydrogen phosphate or calcium hydrogen phosphate
  • the sweetener is saccharin sodium or aspartame
  • the flavor is L-menthol or peppermint
  • the organic acid is caffeic acid
  • the inorganic acid is sodium hydrogen phosphate
  • the sweetener is sodium saccharin sodium.
  • the flavor is preferably L-menthol.
  • the present invention is a pharmaceutical composition containing nateglinide as an active ingredient, which composition further contains an organic or inorganic acid, a sweetener, and a flavor.
  • the organic acid is ascorbic acid, citric acid, citric anhydride, succinic acid, tartaric acid, fumaric acid, or malic acid
  • the inorganic acid is sodium hydrogen carbonate or calcium hydrogen phosphate
  • the sweetener is sucrose.
  • the flavoring agent is L-menthol or peppermint
  • the organic or inorganic acid is citric acid of an organic acid or sodium hydrogen phosphate of an inorganic acid. Is preferably saccharin sodium and the flavor is L-menthol.
  • composition is preferably a pharmaceutical composition which is an orally disintegrating tablet or an orally disintegrating tablet having reduced bitterness.
  • nateglinide which is a diabetic drug, which does not give a bitter taste even when disintegrated in the oral cavity.
  • BEST MODE FOR CARRYING OUT THE INVENTION Nateglinide contained in the pharmaceutical composition of the present invention can be synthesized according to the method described in Japanese Patent Publication No. 4-15221 and the like.
  • the crystal form to be used is not particularly limited. H-type or B-type described in Japanese Patent No. 2508949 is preferred, and particularly H-type is particularly preferable in view of stability.
  • the organic acid contained in the pharmaceutical composition of the present invention refers to an organic compound having an acid property and in the form of a salt, for example, an alkali metal such as sodium and potassium, and an alkaline earth such as calcium and magnesium. It may be in the form of a salt with a metal or an amine such as triethanolamine. Specific examples include ascorbic acid, citric acid, citric anhydride, succinic acid, tartaric acid, fumaric acid, malic acid and their sodium and potassium salts. Ascorbic acid, citric acid, citric anhydride, tartaric acid and malic acid are more preferable in the form of an acid, and cunic acid is particularly preferable from the viewpoint of reducing bitterness.
  • the inorganic acid contained in the pharmaceutical composition of the present invention refers to an acid containing no carbon atom, which is in the form of a salt, for example, an alkali metal such as sodium and potassium, an alkaline earth metal such as calcium and magnesium, and the like. Alternatively, it may be in the form of a salt with an amine such as triethanolamine. Specific examples include phosphoric acid, carbonic acid, sodium hydrogen phosphate, calcium hydrogen phosphate, calcium carbonate and the like. In a salt form, sodium hydrogen phosphate and calcium hydrogen phosphate are more preferable, and sodium hydrogen phosphate is particularly preferable from the viewpoint of reducing bitterness.
  • the sweetener contained in the pharmaceutical composition of the present invention refers to an additive or a seasoning used for imparting sweetness to a pharmaceutical or food, and specifically includes sugars, sugar alcohols, saccharin, saccharin sodium, and aspartame. And saccharin sodium and aspartame are preferred, and saccharin sodium is particularly preferred from the viewpoint of reducing bitterness.
  • the fragrance contained in the pharmaceutical composition of the present invention refers to a substance added to add aroma to pharmaceuticals, foods, cosmetics, etc., and specifically, L-menthol, peppermint powder, melon, citrus fruits, berries, pineapple, vanilla. And coffee, cola, cider, cider, milk, cinnamon, and L-menthol and peppermint powder are preferred, and L-menthol is particularly preferred from the viewpoint of reducing bitterness.
  • Examples of the dosage form of the pharmaceutical composition of the present invention include powders, granules, fine granules, tablets, and the like, and preferred examples include granules, fine granules, and tablets.
  • the pharmaceutical composition of the present invention is preferably in the form of a tablet, and the content of nateglinide per tablet is preferably 30 mg or more!
  • additives used in ordinary oral preparations can be used as other components, and are not particularly limited, but include excipients, disintegrants, binders, Lubricants, coloring agents and the like can be appropriately compounded.
  • the pharmaceutical composition of the present invention is in the form of an orally disintegrating tablet, it is preferable to further add a disintegrant in order to rapidly disintegrate the tablet in the oral cavity.
  • Disintegrators include sodium carboxymethyl starch, canolemelose, canolemelose sodium, canolemelose kanoresum, cross-force noremelose sodium, crospovidone, low-substituted hydroxypropylcellulose (hydroxypropyl group 5.0 to 16.0%; see Japanese Pharmacopoeia 13th revision D—885 to D888), partially alpha-monostarch, and the like, with carmellose, carboxymethyl starch sodium and crospovidone being particularly preferred. ,.
  • the amount of the disintegrant added is preferably 1% by weight to 10,000% by weight, more preferably 5% by weight to 1000% by weight, and still more preferably 10% by weight to 400% by weight, based on nateglinide. is there.
  • the amount of other additives to nateglinide when producing the pharmaceutical composition of the present invention is not particularly limited as long as the object of the present invention can be achieved.
  • 0.1-500% by weight of sweetener and 0.01-50% by weight of flavor More preferably, the content is 1 to 200% by weight of an organic acid, 1 to 200% by weight of an inorganic acid, 1 to 100% by weight of a sweetener, and 1 to 15% by weight of a flavor.
  • the total amount of soybean curd of these soups is 0.001 ⁇
  • the content is 50,000% by weight, preferably 0.01 to 5000% by weight, more preferably 0.1 to 1000% by weight, and still more preferably 1 to 500% by weight.
  • nateglinide is added to nateglinide by 100 to 200% by weight
  • Pharmaceutical compositions containing up to 200% by weight and 5 to 15% by weight of L menthol are preferred.
  • a nateglinide-containing pharmaceutical composition having reduced bitterness can be provided.
  • the pharmaceutical composition of the present invention can ensure bioequivalence in in vitro evaluation with current nateglinide tablets.
  • the method for producing the pharmaceutical composition of the present invention can be produced by tableting a simple mixture of a drug and an additive, and the powder before tableting can be produced by dry granulation or wet granulation. Granulation method and fluidized bed granulation method can be used.
  • an orally disintegrating tablet having reduced bitterness using the above composition it can be produced by using a usual method.
  • a mixture of the composition or a granulated product is produced under low pressure, for example, A tableting method at 50 NZm 2 or less can be used.
  • the composition is mixed with an appropriate mixer, it can be manufactured by low-pressure tableting, or can be produced by dry granulation (pressure granulation, etc.) or wet granulation (fluid bed granulation).
  • Granules can be prepared by a usual granulation method such as a granulation method, a stirring granulation method, etc.) and tableted under low pressure.
  • Orally disintegrating tablets produced by these methods can be ingested without the need for water as compared with the conventional preparations, and have a reduced bitterness even when disintegrated in the oral cavity.
  • the orally disintegrating tablet preferably has a hardness of 50 NZm 2 or less, more preferably 20 to 30 NZm 2 . It is a drug that is rapidly disintegrated by saliva in the oral cavity and can be swallowed with saliva.
  • the formulations of the present invention can disintegrate within 60 seconds.
  • the mixed powders obtained in Examples 1 to 21 and Comparative Examples 1 and 2 were subjected to taste evaluation by sensory evaluation. The evaluation was performed in five stages. Table 2 shows the evaluation criteria and Table 3 shows the taste evaluation results.
  • bitterness could be reduced by adding at least one of organic acids, inorganic acids, sweeteners and flavors.
  • the fluidized bed dryer Dried in Freund Industries, FLO-1.
  • the compound described in the post-addition part in Table 4 is mixed in a bag to prepare granules for tableting.
  • the obtained granules for tableting were tableted at a low pressure (20 to 30 NZm 2 ) with a tableting machine (Hata Tekkosho, HTAP38LII, ⁇ 7.5 mm) to obtain orally disintegrating tablets.
  • Mac stearate "nesium 1.5.1.5.1.5
  • the orally disintegrating tablets obtained in the above Examples were evaluated for taste and measured for orally disintegrating time according to the evaluation criteria described in Table 2. The taste was evaluated on a five-point scale. Oral disintegration time The disintegration time when this tablet was put in the oral cavity was measured. Table 5 shows the evaluation results. As shown in Table 5, the orally disintegrating tablets containing an organic acid (or inorganic acid), a sweetener, and a flavoring agent in the same mixing ratio as the mixed powder and a disintegrant are added. It has the same bitterness-reducing effect as, and has a fast disintegration property with an oral disintegration time of 60 seconds or less.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'intention est de fournir une préparation contenant du natéglinide (en particulier une préparation désagrégée dans la cavité buccale) ayant une amertume amoindrie laquelle est une composition médicinale contenant du natéglinide comme ingrédient actif et caractérisée en ce qu'elle contient en plus au moins un élément choisi dans le groupe constitué d'acides organiques, d'acides inorganiques, d'édulcorants et de parfums.
PCT/JP2005/006459 2004-04-01 2005-04-01 Préparation contenant du natéglinide Ceased WO2005094812A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2006511837A JP5168712B2 (ja) 2004-04-01 2005-04-01 ナテグリニド含有製剤
KR1020067020510A KR101175120B1 (ko) 2004-04-01 2006-09-29 나테글리니드 함유 제제

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004108925 2004-04-01
JP2004-108925 2004-04-01

Publications (1)

Publication Number Publication Date
WO2005094812A1 true WO2005094812A1 (fr) 2005-10-13

Family

ID=35063493

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/006459 Ceased WO2005094812A1 (fr) 2004-04-01 2005-04-01 Préparation contenant du natéglinide

Country Status (3)

Country Link
JP (1) JP5168712B2 (fr)
KR (2) KR20120064735A (fr)
WO (1) WO2005094812A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008057968A3 (fr) * 2006-11-02 2008-09-12 Coca Cola Co Composition antidiabétique renfermant un édulcorant très puissant
US7732492B2 (en) 2003-08-08 2010-06-08 Ajinomoto Co., Inc. Nateglinide-containing preparation
JP2011529445A (ja) * 2008-07-28 2011-12-08 武田薬品工業株式会社 医薬組成物
WO2012147660A1 (fr) 2011-04-28 2012-11-01 田辺三菱製薬株式会社 Comprimé oral à dissolution rapide

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022105A1 (fr) * 1996-11-15 1998-05-28 Ajinomoto Co., Inc. Preparation en comprimes
JPH10298062A (ja) * 1997-04-24 1998-11-10 Pfizer Pharmaceut Co Ltd 口腔内速溶型錠剤
WO1999016470A1 (fr) * 1997-09-30 1999-04-08 Daiichi Pharmaceutical Co., Ltd. Preparation orale
JP2000159691A (ja) * 1998-09-21 2000-06-13 Taisho Pharmaceut Co Ltd 経口用固形製剤
JP2000290199A (ja) * 1999-03-31 2000-10-17 Taisho Pharmaceut Co Ltd 経口用医薬組成物
JP2001069961A (ja) * 1999-09-02 2001-03-21 Fuji Chem Ind Co Ltd 苦味マスキング用組成物
WO2001047557A1 (fr) * 1999-12-28 2001-07-05 Ajinomoto Co., Inc. Preparations orales pour diabetes
WO2002034254A1 (fr) * 2000-10-24 2002-05-02 Ajinomoto Co.,Inc. Preparations contenant du nateglinide
WO2002040010A1 (fr) * 2000-10-24 2002-05-23 Ajinomoto Co.,Inc. Preparations de medicament contenant du nateglinide
JP2002154966A (ja) * 2000-11-22 2002-05-28 Taisho Pharmaceut Co Ltd アセチルサリチル酸アルミニウム含有組成物
JP2002179558A (ja) * 2000-10-06 2002-06-26 Takeda Chem Ind Ltd 固形製剤
JP2003509457A (ja) * 1999-09-17 2003-03-11 ノバルティス アクチエンゲゼルシャフト 代謝障害、とりわけ糖尿病、または糖尿病関連疾患もしくは病状の処置方法
JP2003518496A (ja) * 1999-12-23 2003-06-10 ノバルティス アクチエンゲゼルシャフト グルコース代謝障害を処置するための血糖降下薬の使用
JP2004339071A (ja) * 2003-05-13 2004-12-02 Towa Yakuhin Kk 苦味を低減した口腔内崩壊錠剤
JP2005132788A (ja) * 2003-10-31 2005-05-26 Lion Corp 口腔内崩壊錠
JP2005132801A (ja) * 2003-10-31 2005-05-26 Lion Corp 口腔内崩壊錠

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10304403A1 (de) * 2003-01-28 2004-08-05 Röhm GmbH & Co. KG Verfahren zur Herstellung einer oralen Arzneiform mit unmittelbarem Zerfall und Wirkstofffreisetzung

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998022105A1 (fr) * 1996-11-15 1998-05-28 Ajinomoto Co., Inc. Preparation en comprimes
JPH10298062A (ja) * 1997-04-24 1998-11-10 Pfizer Pharmaceut Co Ltd 口腔内速溶型錠剤
WO1999016470A1 (fr) * 1997-09-30 1999-04-08 Daiichi Pharmaceutical Co., Ltd. Preparation orale
JP2000159691A (ja) * 1998-09-21 2000-06-13 Taisho Pharmaceut Co Ltd 経口用固形製剤
JP2000290199A (ja) * 1999-03-31 2000-10-17 Taisho Pharmaceut Co Ltd 経口用医薬組成物
JP2001069961A (ja) * 1999-09-02 2001-03-21 Fuji Chem Ind Co Ltd 苦味マスキング用組成物
JP2003509457A (ja) * 1999-09-17 2003-03-11 ノバルティス アクチエンゲゼルシャフト 代謝障害、とりわけ糖尿病、または糖尿病関連疾患もしくは病状の処置方法
JP2003518496A (ja) * 1999-12-23 2003-06-10 ノバルティス アクチエンゲゼルシャフト グルコース代謝障害を処置するための血糖降下薬の使用
WO2001047557A1 (fr) * 1999-12-28 2001-07-05 Ajinomoto Co., Inc. Preparations orales pour diabetes
JP2002179558A (ja) * 2000-10-06 2002-06-26 Takeda Chem Ind Ltd 固形製剤
WO2002040010A1 (fr) * 2000-10-24 2002-05-23 Ajinomoto Co.,Inc. Preparations de medicament contenant du nateglinide
WO2002034254A1 (fr) * 2000-10-24 2002-05-02 Ajinomoto Co.,Inc. Preparations contenant du nateglinide
JP2002154966A (ja) * 2000-11-22 2002-05-28 Taisho Pharmaceut Co Ltd アセチルサリチル酸アルミニウム含有組成物
JP2004339071A (ja) * 2003-05-13 2004-12-02 Towa Yakuhin Kk 苦味を低減した口腔内崩壊錠剤
JP2005132788A (ja) * 2003-10-31 2005-05-26 Lion Corp 口腔内崩壊錠
JP2005132801A (ja) * 2003-10-31 2005-05-26 Lion Corp 口腔内崩壊錠

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7732492B2 (en) 2003-08-08 2010-06-08 Ajinomoto Co., Inc. Nateglinide-containing preparation
WO2008057968A3 (fr) * 2006-11-02 2008-09-12 Coca Cola Co Composition antidiabétique renfermant un édulcorant très puissant
JP2010509232A (ja) * 2006-11-02 2010-03-25 ザ・コカ−コーラ・カンパニー 高甘味度甘味料を含む抗糖尿病組成物
JP2014139224A (ja) * 2006-11-02 2014-07-31 The Coca-Cola Company 高甘味度甘味料を含む抗糖尿病組成物
JP2011529445A (ja) * 2008-07-28 2011-12-08 武田薬品工業株式会社 医薬組成物
US9186411B2 (en) 2008-07-28 2015-11-17 Takeda Pharmaceutical Company Limited Pharmaceutical composition
WO2012147660A1 (fr) 2011-04-28 2012-11-01 田辺三菱製薬株式会社 Comprimé oral à dissolution rapide

Also Published As

Publication number Publication date
KR20060134144A (ko) 2006-12-27
KR20120064735A (ko) 2012-06-19
KR101175120B1 (ko) 2012-08-21
JP5168712B2 (ja) 2013-03-27
JPWO2005094812A1 (ja) 2008-02-14

Similar Documents

Publication Publication Date Title
JP4801255B2 (ja) 沸騰性酸−塩基対を含有する製薬学的組成物
US6187336B1 (en) Process for producing a solid which is rapidly soluble in the oral cavity
KR101203186B1 (ko) 약물의 맛이 차폐된 경구용 약학 조성물 및 그 제조 방법
WO2000047233A1 (fr) Comprimes se desintegrant rapidement dans la cavite buccale
JP5342028B2 (ja) 口腔内崩壊錠
JPWO2000047233A1 (ja) 口腔内で速やかに崩壊する錠剤
WO2002069934A1 (fr) Préparations se délitant rapidement dans la bouche
JP5859664B2 (ja) 薬物の味がマスクされた経口用薬学組成物及びその製造方法
EP2218443A1 (fr) Comprimé se désintégrant oralement
EP2050448A1 (fr) Comprime a desagregation orale ayant un gout amer masque et son procede de production
WO2007086457A1 (fr) Comprimé à désagrégation rapide produit par pastillage direct à sec
JP2010270110A (ja) ネオテームを含有する経口製剤
JP4090997B2 (ja) ペリンドプリルの口内分散性薬剤組成物
JP2004269513A (ja) 固形製剤
WO2005029980A1 (fr) Composition ou l'odeur et le gout desagreable des cysteines sont attenues
JP2005060309A (ja) 不快な味を低減した口腔内崩壊錠剤
JP2010241760A (ja) 不快な味の軽減された口腔内速崩壊錠及びその製造方法
JP5168712B2 (ja) ナテグリニド含有製剤
CN102258490A (zh) 布洛芬咀嚼片
JP2010280645A (ja) γ−アミノ酪酸含有経口用組成物
JP5201837B2 (ja) 口腔内速崩壊錠
JP5563841B2 (ja) 薬物の不快な味をマスキングした経口医薬組成物
CN115666516A (zh) 包括卡培他滨的快速分散药物组合物
JP2002536401A (ja) メタミゾール含有起泡性医薬組成物
JP7263151B2 (ja) 経口組成物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006511837

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 1020067020510

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

WWP Wipo information: published in national office

Ref document number: 1020067020510

Country of ref document: KR

122 Ep: pct application non-entry in european phase